Literature DB >> 8484962

Complementation analysis of patients with intact peroxisomes and impaired peroxisomal beta-oxidation.

M C McGuinness1, A B Moser, B T Poll-The, P A Watkins.   

Abstract

Complementation analysis, using peroxisomal beta-oxidation of very long chain fatty acids (VLCFA) as the criterion for complementation, is useful in the study of patients who are suspected of having a single enzyme defect in the peroxisomal beta-oxidation pathway. Laboratory findings for these patients include elevated plasma VLCFA and impaired VLCFA oxidation in fibroblasts. Some of these patients have slightly abnormal phytanic acid oxidation in fibroblasts. In addition, elevated levels of bile acid intermediates have been reported in some cases. Plasmalogen synthesis, pipecolic acid levels, and subcellular distribution of catalase are normal. Using complementation analysis, we show that six patients, who were suspected of having a single enzyme defect in the peroxisomal beta-oxidation pathway, are deficient in peroxisomal bifunctional enzyme [enoyl-CoA hydratase (EC 4.2.1.17)/3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35)] activity. This group of six patients, deficient in bifunctional enzyme activity, may be subdivided into two complementation groups. It would appear that patients in each of these two groups are deficient in only one of the bifunctional enzyme activities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484962     DOI: 10.1006/bmmb.1993.1025

Source DB:  PubMed          Journal:  Biochem Med Metab Biol        ISSN: 0885-4505


  11 in total

Review 1.  Zellweger syndrome and associated phenotypes.

Authors:  D R FitzPatrick
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

2.  Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency.

Authors:  E G van Grunsven; E van Berkel; L Ijlst; P Vreken; J B de Klerk; J Adamski; H Lemonde; P T Clayton; D A Cuebas; R J Wanders
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 3.  Peroxisomal disorders: a review.

Authors:  B Fournier; J A Smeitink; L Dorland; R Berger; J M Saudubray; B T Poll-The
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 4.  Very long chain fatty acids in higher animals--a review.

Authors:  A Poulos
Journal:  Lipids       Date:  1995-01       Impact factor: 1.880

5.  Altered expression of ALDP in X-linked adrenoleukodystrophy.

Authors:  P A Watkins; S J Gould; M A Smith; L T Braiterman; H M Wei; F Kok; A B Moser; H W Moser; K D Smith
Journal:  Am J Hum Genet       Date:  1995-08       Impact factor: 11.025

6.  Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal beta-oxidation defects.

Authors:  B C Paton; P C Sharp; D I Crane; A Poulos
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

7.  Studies on the oxidation of phytanic acid and pristanic acid in human fibroblasts by acylcarnitine analysis.

Authors:  N M Verhoeven; C Jakobs; H J ten Brink; R J Wanders; C R Roe
Journal:  J Inherit Metab Dis       Date:  1998-10       Impact factor: 4.982

8.  Complementation analysis in patients with the clinical phenotype of a generalised peroxisomal disorder.

Authors:  S J Steinberg; A H Fensom
Journal:  J Med Genet       Date:  1996-04       Impact factor: 6.318

9.  Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis.

Authors:  E G van Grunsven; E van Berkel; P A Mooijer; P A Watkins; H W Moser; Y Suzuki; L L Jiang; T Hashimoto; G Hoefler; J Adamski; R J Wanders
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

10.  Dataset for a case report of a homozygous PEX16 F332del mutation.

Authors:  Carlos Bacino; Yu-Hsin Chao; Elaine Seto; Tim Lotze; Fan Xia; Richard O Jones; Ann Moser; Michael F Wangler
Journal:  Data Brief       Date:  2015-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.